Addex Therapeutics Ltd. (ADXN) stock
ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.06−0.44 (-12.57%)
Close on Nov 18, 2026Market cap $62.83KP/E –Yield –
Earnings
Addex Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Addex Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Apr 30, 2026before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Apr 25, 2025before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 18, 2024before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Addex Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Addex Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Addex Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?